Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus Bendamustine and Rituximab in Untreated MCL
NCT03834688Phase 2Completed
- Sponsor
- PrECOG
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in mantle cell lymphoma (MCL), sponsored by PrECOG. Primary endpoint: Complete Response Rate at End of Induction at 6 months. Started Jan 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03834688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834688.